Bellicum pharmaceuticals awarded $ 5.7 million of the cancer prevention and Research Institute of Texas

Current article ratings:
Patients / public:healthcare Prof:
Bellicum pharmaceuticals, Inc. today announced that the company notice of a $5.7 million companies marketing received award of the cancer prevention and Research Institute of Texas ("CPRIT"). Bellicum was the only company for the financing of this second round of the programme award recommended commercialization. The award will finance staff, production and clinical trial of Bellicum's CaspaCIDe ™ therapy that promises to improve results for late stage of cancer patients.

CPRIT was, cancer research innovation and marketing to speed up and improve access to evidence-based prevention programs and services throughout the State. Commercialisation company premiums, an important part of the Institute are initiative to support the further development of the most promising ways to the approval and launch. The State has announced more than $500 million in awards and the appropriations for innovative cancer research and prevention programs.

The application review process include detailed evaluation by scientific and commercialization experts, followed by regulatory, product development and intellectual property due diligence. Accepting the award is subject to the conclusion of the contract negotiations. "We are for a significant was 5.7 million US dollars award of CPRIT have recommended our novel therapy for patients with high-risk types of cancer to promote", said CEO Tom Farrell. "We are particularly pleased this notice the strict validation of our use of the CPRIT check Marketing Council, whose members have been significant scientific, venture capital and commercial experience."

The award is the clinical development of CaspaCIDe ™, Bellicum's solution to the problem of Graft versus host disease (GvHD), a debilitating and often fatal side effect of bone marrow transplant support. Originally developed by Bellicum CSO Dr. David Spencer, Vice Chair of pathology and Immunology at Baylor College of medicine, and advanced in clinical studies by Dr. Malcolm Brenner, Director of the Center for cell and gene therapy works at the Baylor College of MedicineCaspaCIDe ™ by the transplant physician, eliminated selectively transplanted cells that cause that GvHD. building on promising early clinical results seen in Dr. Brenner's "CASPALLO" trial, the CPRIT award the execution of a randomized, double-blind clinical study will support in patients with high risk of hematologic malignancies.

"For cancer patients at high risk leukemia and Lymphoma, a bone marrow transplant offers a chance for a cure, but the procedure mortality is high," said Dr. Kevin founder, Chairman and CMO Bellicum decided. "In this application CaspaCIDe ™ offers a fast and effective means of resolving GvHD, which number one problem of facing transplant patients and their doctors today." "More broadly, the potential, medicine has enabled a variety of new, safe and effective cell therapies."

Source: Bellicum pharmaceuticals, Inc.